Immuno-Oncology | Specialty

Avelumab Shows Promise in Early Trial for Advanced Ovarian Cancer

July 19th 2016

Avelumab, a fully human anti–PD-L1 IgG1 antibody, showed activity in patients with heavily pretreated recurrent or refractory ovarian cancer with an acceptable toxicity profile.

Expert Enthusiastic About Immunotherapy in SCLC

July 18th 2016

Raffaele Califano, MD, discusses the KEYNOTE-028 and CheckMate-032 trials, the role of PD-L1 as a biomarker in small cell lung cancer, and what is on the horizon for immunotherapies in the landscape of SCLC.

Patnaik Highlights Evolution Toward Immunotherapy in Prostate Cancer

July 18th 2016

Akash Patnaik, MD, discusses immunotherapy and personalized medicine tactics in the field of prostate cancer, as well as the work that needs to be done with existing targeted therapies and biomarker development.

FDA Grants Nivolumab Priority Review for Head and Neck Cancer

July 18th 2016

The FDA has granted a priority review designation to nivolumab as a treatment for patients with previously treated metastatic or recurrent squamous cell carcinoma of the head and neck.

Dr. Randy Sweis on Impact of Atezolizumab Approval in Bladder Cancer

July 15th 2016

Expert Shares Potential of Durvalumab in Patients With Urothelial Bladder Cancer

July 15th 2016

Saeed Rafii, MD, PhD, MRCP, discusses the PD-L1 inhibitor durvalumab, the encouraging findings of it in Study 1108, and the evolving landscape of bladder cancer.

Dr. Elizabeth Plimack on Nivolumab in Kidney Cancer

July 15th 2016

O'Donnell Discusses IMvigor Findings, Excitement Over Atezolizumab Approval in mUC

July 14th 2016

Peter O'Donnell, MD, discusses the encouraging IMvigor 210 results, the impact of atezolizumab (Tecentriq) in the treatment landscape, and the role of immunotherapy in metastatic urothelial carcinoma.

Immunotherapy Potential Continues to Grow in Gastric Cancers

July 14th 2016

Hendrik-Tobias Arkenau, MD, PhD, discusses the significance of the JAVELIN results for gastrointestinal cancer, the potential for CTLA-4 and PD-1/PD-L1 combinations, and the promise of pembrolizumab (Keytruda) in colorectal cancer.

Dr. Rosenberg on Future Use of Atezolizumab in Bladder Cancer

July 13th 2016

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses ongoing research of and next steps with atezolizumab (Tecentriq) for the treatment of patients with metastatic urothelial carcinoma.

Pembrolizumab Shows Potential in Advanced Thyroid Cancer

July 12th 2016

Pembrolizumab (Keytruda) demonstrated promising antitumor activity with durable responses in patients with advanced thyroid cancer.

Dr. Jonathan Trent on Engineered T- cell Therapy in Sarcoma

July 9th 2016

Clinical Hold Placed on Phase II Trial for JCAR015 in Adult ALL

July 9th 2016

The FDA has placed a clinical hold on a phase II study exploring the CD19-targeted CAR-T cell therapy JCAR015 for adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.

Potential Biomarkers Identified for Pembrolizumab in Head and Neck Cancer

July 8th 2016

PD-L2 and the IFN-γ 6-gene signature may offer options beyond PD-L1 to predict response to pembrolizumab (Keytruda) in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Dr. Thierry Jahan on the CRS-207 Vaccine in Mesothelioma

July 7th 2016

​Thierry M. Jahan, MD, a clinical professor in the Department of Medicine at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib trial of CRS-207 in malignant pleural mesothelioma (MPM).

Dr. Nanus on Next Steps With Atezolizumab in Patients With mUC

July 7th 2016

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses the unanswered questions that remain with atezolizumab (Tecentriq) in patients with metastatic urothelial carcinoma (mUC).

Final Thoughts on Immunotherapy

July 6th 2016

The Next Wave in Checkpoint Inhibition

July 6th 2016

Oncolytic Viruses: Melanoma and Bladder Cancer

July 6th 2016

Managing Immunotherapy-Related Toxicity

July 6th 2016